Search results for "Lymphocyte Count"

showing 10 items of 140 documents

Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium

2015

<b><i>Background:</i></b> The role of mitogen-activated protein kinases (MAPK) in regulating the inflammatory response in the airways of patients with chronic obstructive pulmonary disease (COPD) and asthmatic patients is unclear. <b><i>Objectives:</i></b> To investigate the expression of activated MAPK in lungs of COPD patients and in bronchial biopsies of asthmatic patients and to study MAPK expression in bronchial epithelial cells in response to oxidative and inflammatory stimuli. <b><i>Methods:</i></b> Immunohistochemical expression of phospho (p)-p38 MAPK, p-JNK1 and p-ERK1/2 was measured in bronchial mucosa in pat…

P38 MAPKMaleMAPK/ERK pathwayAsthma phenotypeSMOKERespiratory SystemMitogen-activated protein kinases; p65; Pathology of chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease phenotypes; Asthma phenotypesPathology of chronic obstructive pulmonary diseasep38 Mitogen-Activated Protein KinasesChronic obstructive pulmonary disease phenotypePulmonary Disease Chronic ObstructiveOXIDATIVE STRESSMACROPHAGESRespiratory systemMitogen-activated protein kinasesChronic obstructive pulmonary disease phenotypesMitogen-activated protein kinases; p65; pathology of chronic obstructive pulmonary disease phenotypes; asthma phenotypesCOPDp65KinaseAsthma phenotypes; Chronic obstructive pulmonary disease phenotypes; Mitogen-activated protein kinases; p65; Pathology of chronic obstructive pulmonary disease; Pulmonary and Respiratory MedicineACTIVATED PROTEIN-KINASEInterleukinMiddle AgedImmunohistochemistrypathology of chronic obstructive pulmonary disease phenotypesAsthma phenotypesFemaleLife Sciences & BiomedicinePulmonary and Respiratory Medicinep38 mitogen-activated protein kinasesBlotting WesternINHIBITIONSocio-culturaleBronchiRespiratory MucosaOBSTRUCTIVE PULMONARY-DISEASE1102 Cardiovascular Medicine And HaematologyCell LinemedicineHumansLymphocyte CountInterleukin 8AgedAsthmaScience & Technologybusiness.industryInterleukin-8Transcription Factor RelAPATHWAYSMitogen-activated protein kinasemedicine.diseaseAsthmarespiratory tract diseasesSEVERITYCase-Control StudiesCELLSImmunologybusiness
researchProduct

Factors Associated with Nonsuppression of HIV Infection in the Spanish VACH Cohort.

2020

We aim to determine the prevalence of HIV nonsuppression and factors associated with it. This is a cross-sectional multicenter study carried out in January 2016 with data of the VACH Cohort, a registry participated by 23 hospitals from most regions of Spain. The prevalence of HIV nonsuppression, defined as HIV RNA ≥200 copies/mL, is documented. The possible association of HIV nonsuppression with sociodemographic and clinical variables is assessed with a logistic regression analysis. A total of 30,843 adult patients are included; 7,358 of them (23.86%) have nonsuppressed HIV. An association is found between nonsuppression of HIV and the following variables: lower body mass index, lower age o…

Pediatricsmedicine.medical_specialtybusiness.industryCoinfectionImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsViral Loadmedicine.disease_causeCD4 Lymphocyte CountInfectious DiseasesCross-Sectional StudiesMulticenter studyAnti-Retroviral AgentsRisk FactorsVirologyChild PreschoolCohortMedicineHumansbusinessAIDS research and human retroviruses
researchProduct

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2020

Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC an…

RNA virusesMaleEtiologyCancer TreatmentHepacivirusKaplan-Meier EstimateBiochemistryCohort StudiesWhite Blood CellsMathematical and Statistical TechniquesRetrospective StudieAnimal CellsAdult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib; Nutrition AssessmentMedicine and Health Sciences80 and overLymphocytesPathology and laboratory medicineAged 80 and overHepatitis C virusLiver DiseasesStatisticsQLiver NeoplasmsRMedical microbiologyMiddle AgedSorafenibPrognosisOncologyItalyLiver NeoplasmPhysical SciencesVirusesMedicineFemalePathogensCellular TypesHumanResearch ArticleAdultHepatitis B virusCarcinoma HepatocellularImmune CellsScienceImmunologyAntineoplastic AgentsGastroenterology and HepatologySerum Albumin ...Research and Analysis MethodsCarcinomasMicrobiologyAlbuminsGastrointestinal TumorsHumansLymphocyte CountStatistical MethodsSerum AlbuminAgedRetrospective StudiesBlood CellsAdult Aged 80 and over Antineoplastic Agents Carcinoma Hepatocellular Cohort Studies Female Humans Italy Kaplan-Meier Estimate Liver Neoplasms Lymphocyte Count Male Middle Aged Prognosis Retrospective Studies Serum Albumin Sorafenib Nutrition AssessmentBiology and life sciencesFlavivirusesCarcinomaViral pathogensOrganismsCancers and NeoplasmsProteinsHepatocellularHepatocellular CarcinomaCell Biologyprognostic nutritional index (PNI) hepatocellular carcinoma (HCC) sorafenib. survival mRECISTHepatitis virusesMicrobial pathogensNutrition AssessmentMultivariate AnalysisCohort StudieMathematics
researchProduct

Peripheral Frequency of CD4+ CD28- Cells in Acute Ischemic Stroke: Relationship With Stroke Subtype and Severity Markers.

2015

CD4+ CD28− T cells also called CD28 null cells have been reported as increased in the clinical setting of acute coronary syndrome. Only 2 studies previously analyzed peripheral frequency of CD28 null cells in subjects with acute ischemic stroke but, to our knowledge, peripheral frequency of CD28 null cells in each TOAST subtype of ischemic stroke has never been evaluated. We hypothesized that CD4+ cells and, in particular, the CD28 null cell subset could show a different degree of peripheral percentage in subjects with acute ischemic stroke in relation to clinical subtype and severity of ischemic stroke. The aim of our study was to analyze peripheral frequency of CD28 null cells in subjects…

RiskAcute coronary syndromemedicine.medical_specialtySettore MED/09 - Medicina InternaObservational Study5300Severity of Illness IndexArticleBrain IschemiaBrain ischemiaCD28 AntigensInternal medicineSeverity of illnessmedicineNull cellHumanscardiovascular diseasesStrokeAgedbusiness.industryCase-control studyCD28General MedicineFlow Cytometrymedicine.diseaseLymphocyte Subsetsstroke CD4+ CD28-CD4 Lymphocyte CountPeripheralStrokeCardiovascular DiseasesCase-Control StudiesPhysical therapyCardiologybusiness
researchProduct

Increased frequencies of CD11b+CD33+CD14+HLA-DRlowmyeloid-derived suppressor cells are an early event in melanoma patients

2014

Myeloid-derived suppressor cells (MDSC) are a heterogeneous cell population characterized by immunosuppressive activity. Elevated levels of MDSC in peripheral blood are found in inflammatory diseases as well as in malignant tumors where they are supposed to be major contributors to mechanisms of tumor-associated tolerance. We investigated the frequency and function of MDSC in peripheral blood of melanoma patients and observed an accumulation of CD11b(+) CD33(+) CD14(+) HLA-DR(low) MDSC in all stages of disease (I-IV), including early stage I patients. Disease progression and enhanced tumor burden did not result in a further increase in frequencies or change in phenotype of MDSC. By investig…

Skin Neoplasmsmedicine.medical_treatmentCD14Sialic Acid Binding Ig-like Lectin 3CD33PopulationLipopolysaccharide ReceptorsReceptors Antigen T-CellDermatologyBiologyLymphocyte ActivationT-Lymphocytes RegulatoryBiochemistryImmune toleranceTetanus ToxoidHLA-DRmedicineHumansMyeloid CellsLymphocyte CounteducationMelanomaMolecular BiologyCells CulturedCell ProliferationNeoplasm Stagingeducation.field_of_studyCD11b AntigenMelanomaInterleukin-8HLA-DR AntigensImmunotherapymedicine.diseaseCoculture TechniquesTumor BurdenCase-Control StudiesImmunologyDisease ProgressionLeukocytes MononuclearMyeloid-derived Suppressor CellTumor EscapeExperimental Dermatology
researchProduct

Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.

1997

Abstract The current study was carried out to elucidate the immunoregulatory changes induced by venom immunotherapy (VIT) in bee or wasp allergic subjects. All subjects included in this study had a history of severe systemic allergic reactions to stings of the respective insect as well as positive skin tests with the respective venom or venom-specific IgE in the sera. Parameters assessed in peripheral blood mononuclear cells (PBMC) before and after initiation of VIT (rush therapy reaching a maintenance dose of 100 micrograms venom injected subcutaneously within 1 week) were expression of CD3, CD4, CD8, CD45RA, CD45RO, interleukin (IL)-2 receptor (R) alpha, IL-4R, IL-12R, Fc epsilon RII, CD4…

Time Factorsmedicine.medical_treatmentImmunologyCD40 LigandDown-RegulationVenomWasp VenomsImmunoglobulin ELigandsLymphocyte ActivationPeripheral blood mononuclear cellInterferon-gammaTh2 CellsAntigens CDT-Lymphocyte SubsetsmedicineImmunology and AllergyHumansLymphocyte CountRNA MessengerCD40 AntigensCD40Membrane GlycoproteinsbiologyReceptors IgEInterleukinAntibodies MonoclonalInsect Bites and StingsReceptors InterleukinAllergensTh1 CellsInterleukin-10Receptors Interleukin-4Interleukin 10Bee VenomsCytokineDesensitization ImmunologicImmunologyAntigens Surfacebiology.proteinInterleukin-4AntibodyEuropean journal of immunology
researchProduct

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

2010

The potent anti-tumour activities of gamma delta T cells have prompted the development of protocols in which gamma delta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a V gamma 9V delta 2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of V gamma 9V delta 2 T …

Translational Studiesmedicine.medical_treatmentLymphocyte ActivationZoledronic AcidMetastasisTNF-Related Apoptosis-Inducing LigandProstate cancerT-Lymphocyte SubsetsImmunology and AllergyMedicineDiphosphonatesRemission InductionEsterasesImidazolesReceptors Antigen T-Cell gamma-deltaMiddle AgedMetastatic breast cancerTreatment Outcomemedicine.anatomical_structureDisease ProgressionCytokinesFemaleImmunotherapyBreast diseaseChemokinesT cellImmunologyBreast NeoplasmsInterferon-gammaHemiterpenesOrganophosphorus CompoundsBreast cancerAdjuvants ImmunologicVgamma9Vdelta2 T cells Zoledronate interleukin-2advanced breast cancer patientsHumansLymphocyte CountAgedCell ProliferationSalvage Therapybusiness.industryLysineMucin-1CancerImmunotherapymedicine.diseaseTumor Necrosis Factor Receptor Superfamily Member 7ImmunologyInterleukin-2Leukocyte Common Antigensbusiness
researchProduct

Impact of viable CD45 cells infused on lymphocyte subset recovery after unrelated cord blood transplantation in children

2010

International audience; We studied lymphocyte recovery in 88 children who consecutively underwent unrelated cord blood transplantation for malignant (n = 64) or nonmalignant (n = 24) diseases. All children but 3 received myeloablative conditioning regimens with pretransplant antithymocyte globulin. Median age was 5.6 years (0.1-18 years) and median follow-up was 40 months (10-136 months). The median dose of infused viable CD45(+) cells (vCD45) was 3.35 × 10(7)/kg with a ratio infused vCD45/collected total nucleated cell at 0.46. Immunologic endpoints were: time to achieve CD3(+) >500 and 1500/mm(3), CD4(+) >500/mm(3), CD8(+) >250/mm(3), CD19(+) >200/mm(3), natural killer >100/mm(3). These e…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyLymphocyteMESH: Antigens CD/analysisCell Count[SDV.GEN] Life Sciences [q-bio]/GeneticsMESH : Child PreschoolGastroenterology0302 clinical medicineMESH : ChildMESH: Child[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyChildChildrenMESH : Lymphocyte Count0303 health sciencesMESH : Cell SurvivalbiologyIncidence (epidemiology)Graft Survival[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematology3. Good healthMESH: Hematologic Diseases/therapy Humansmedicine.anatomical_structureQuartileMESH: Cell SurvivalMESH: Cord Blood Stem Cell Transplantation/methodsLymphocytes recoveryChild PreschoolMESH : Immunophenotyping[SDV.IMM]Life Sciences [q-bio]/ImmunologyMESH: Infant KineticsCord Blood Stem Cell Transplantationmedicine.medical_specialtyMESH: Lymphocyte CountGlobulinMESH: ImmunophenotypingAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyCell SurvivalContext (language use)MESH : Hematologic Diseases/therapy HumansCD19Immunophenotyping03 medical and health sciencesMESH : Lymphocyte Subsets/cytologyAntigens CDInternal medicineMESH : AdolescentmedicineHumansLymphocyte CountMESH : Infant KineticsMESH : Antigens CD45* Cell Count030304 developmental biologyMESH: AdolescentTransplantation[SDV.GEN]Life Sciences [q-bio]/GeneticsUmbilical cord blood transplantationMESH : Graft Survival/immunologybusiness.industryUmbilical Cord Blood TransplantationMESH: Child PreschoolMESH : Cord Blood Stem Cell Transplantation/methodsInfantMESH : Antigens CD/analysisHematologic DiseasesLymphocyte SubsetsSurgeryMESH: Lymphocyte Subsets/cytologyKineticsbiology.proteinMESH: Antigens CD45* Cell CountLeukocyte Common Antigensbusiness[ SDV.GEN ] Life Sciences [q-bio]/GeneticsMESH: Graft Survival/immunologyCD8030215 immunology
researchProduct

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

2020

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional surviva…

macro-vascular portal vein invasionMaleCarcinoma HepatocellularAntineoplastic Agentsextra hepatic disease and BCLCsurvivalNLRAntineoplastic AgentCohort Studiesalpha-fetoproteinHumansLymphocyte CountSurvivorsprognostic factorAgedLiver NeoplasmsMiddle AgedSorafenibProgression-Free SurvivalItalyLiver Neoplasmalpha-fetoprotein; extra hepatic disease and BCLC; hepatitis C; macro-vascular portal vein invasion; NLR; prognostic factor; survivalFemaleCohort Studiehepatitis CCarcinoma Hepatocellular ...Liver Neoplasms ...Human
researchProduct

ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA

2012

multiple myelomalymphocyte count
researchProduct